Eribulin was kindly provided by Eisai Inc. (Tokyo, Japan) and Sapporo Medical University for in vitro and in vivo use, respectively. MK-2206 was obtained from ChemScene (Monmouth, NJ, USA). Pazopanib was obtained from AdooQ BioScience (Manassas, VA, USA). Stock solutions of these reagents were generated by dissolving the powder in 100% dimethyl sulfoxide (DMSO; Sigma–Aldrich St. Louis, MO, USA) at 10 mM. HT1080, SK-LMS-1 and SW872 cell lines were purchased from ATCC (Manassas, VA, USA). Both cell lines were maintained in DMEM (Sigma–Aldrich) containing 10% fetal bovine serum, 1% penicillin–streptomycin and 2 μM L-glutamine.
Pazopanib
Manufactured by Adooq
Sourced in United States
Pazopanib is a pharmaceutical compound that functions as a tyrosine kinase inhibitor. It is utilized in the development and research of various laboratory applications.
Automatically generated - may contain errors
Lab products found in correlation
Sw872, by American Type Culture Collection (1 mentions)
Mk 2206, by ChemScene (1 mentions)
Sk lms 1, by American Type Culture Collection (1 mentions)
Ht1080, by American Type Culture Collection (1 mentions)
Dulbecco modified eagle medium (dmem), by Merck Group (1 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)
Eribulin, by Eisai (1 mentions)
Cell counting kit 8 (cck8), by Dojindo Laboratories (1 mentions)
Trametinib, by Adooq (1 mentions)
Ruxolitinib, by Adooq (1 mentions)
Afatinib, by Adooq (1 mentions)
Dasatinib, by Adooq (1 mentions)
Lenvatinib, by Adooq (1 mentions)
Regorafenib, by LGC (1 mentions)
Gefitinib, by Cayman Chemical (1 mentions)
Elacridar, by LGC (1 mentions)
Ponatinib, by Adooq (1 mentions)
Dabrafenib, by Adooq (1 mentions)
Carfilzomib, by Adooq (1 mentions)
Vemurafenib, by Adooq (1 mentions)
3 protocols using pazopanib
1
Evaluating Eribulin, MK-2206, and Pazopanib in Sarcoma Cell Lines
2
Pazopanib Inhibitory Potency in Sarcoma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pazopanib was purchased from Adooq Bioscience (GW-786034). Pazopanib was diluted in dimethyl sulfoxide to 10 mM and the required concentrations were added to the respective media.
Using a 96-well plate, the following cell numbers of each sarcoma cell line were seeded in individuals wells: 2,500 of SW872, 500 of HT1080, 3,000 of SK-LMS-1, 2,000 of A204, 2,500 of RD, 2,000 of ISO-HAS-B, 1,000 of S462, 2,000 of FMS-1, 1,000 of SFT8611, 2,500 of SFT9817, 2,500 of HS-sch2, 3,000 of YST-1, 2,000 of HS-SY-II, 3,000 of Yamato-SS, 2,000 of SaOs2, and 1,000 of MG-63. To calculate the Pazopanib inhibitory potency (IC50) for the 16 sarcoma cell lines, at least seven different doses of Pazopanib were used. Cells were treated with Pazopanib and were seeded 24 h after onto the plates. The cell viability was measured after 72 h using the Cell Counting Kit-8 (Dojindo Laboratories), according to the manufacturer's protocol. Cell viability (%) was calculated by dividing the median value for each Pazopanib dose (conducted at least in triplicates) by the value of untreated cells. IC50 values were calculated using the dosages from the two-cell viability values surrounding 50%. From the results obtained from three or more independent experiments, we calculated the IC50 data.
Using a 96-well plate, the following cell numbers of each sarcoma cell line were seeded in individuals wells: 2,500 of SW872, 500 of HT1080, 3,000 of SK-LMS-1, 2,000 of A204, 2,500 of RD, 2,000 of ISO-HAS-B, 1,000 of S462, 2,000 of FMS-1, 1,000 of SFT8611, 2,500 of SFT9817, 2,500 of HS-sch2, 3,000 of YST-1, 2,000 of HS-SY-II, 3,000 of Yamato-SS, 2,000 of SaOs2, and 1,000 of MG-63. To calculate the Pazopanib inhibitory potency (IC50) for the 16 sarcoma cell lines, at least seven different doses of Pazopanib were used. Cells were treated with Pazopanib and were seeded 24 h after onto the plates. The cell viability was measured after 72 h using the Cell Counting Kit-8 (Dojindo Laboratories), according to the manufacturer's protocol. Cell viability (%) was calculated by dividing the median value for each Pazopanib dose (conducted at least in triplicates) by the value of untreated cells. IC50 values were calculated using the dosages from the two-cell viability values surrounding 50%. From the results obtained from three or more independent experiments, we calculated the IC50 data.
3
Cell-based Assay of Multi-Targeted Kinase Inhibitors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Regorafenib, M-2, M-5, and elacridar were purchased from Toronto Research Chemicals (North York, ON). Ko143 was from Sigma-Aldrich (St. Louis, MO). Imatinib mesylate was from Focus Biomolecules (Plymouth Meeting, PA). Afatinib, bortezomib, cabozantinib, carfilzomib, dabrafenib, dacomitinib, dasatinib, lapatinib, lenvatinib, pazopanib, ponatinib, ruxolitinib, tofacitinib, trametinib, vandetanib, and vemurafenib were from AdooQ Bioscience (Irvine, CA). Sorafenib was from LKT Laboratories Inc. (St. Paul, MN). Sunitinib was from Synkinase Pty Ltd. (San Diego, CA). Crizotinib was from LC Laboratories Inc. (Woburn, MA). Gefitinib and erlotinib were from Cayman Chemical Company (Ann Arbor, MI). Nilotinib was from ChemScene, LLC (Monmouth Junction, NJ). All other chemicals and reagents were of analytical grade and were obtained from commercial sources.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!